Thanks! Very interesting. The only thing I would assume is that the PSA decline would be greater with repeated dosing.
If anything, the rational view may be to expect TLX591 to perform the same as Pluvicto. However, that is only an OK result given the headstart on the market that Pluvicto will have.
Ann: Q3 2023 Business Update to Accompany Quarterly Results, page-63
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.75 |
Change
0.230(1.18%) |
Mkt cap ! $6.609B | |||
| Open | High | Low | Value | Volume |
| $19.85 | $20.00 | $19.67 | $21.81M | 1.101M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1242 | $19.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.75 | 15196 | 1 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| TLX (ASX) Chart |